![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 11, 2016 5:41:18 PM
While extremely subtle It may again show how impressed the FDA is with MNTA's analytics as their thinking evolves in the evaluation and approval of generic biologics under the 351(k) pathway.
Although, not likely to affect other biosimilar players nearly as positively IMO since MNTA has been the only one that has articulated and pursued a "bio-same" with "fingerprint" similarity and fully interchangeable strategy in contrast to just a "bio-similar" generic strategy (similar to the traditional compounds business) pursued by almost all other players.
While still early to draw meaningful conclusions it would seem that though Novartis was first out of the gates with an approved biosimilar its uptake has been less than stellar - likely because its not rated as interchangeable....so the just generic biosimilar strategy may not prove to be the winning formula in approaching the complex biologics generics business.
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM